Razazi et al reported a number of risk factors associated with a patient in the intensive care unit (ICU) being colonized with an extended-spectrum beta-lactamase (ESBL) producing Enterobacteria. These can help to identify a patient who may benefit from surveillance and targeted therapy. The authors are from CHU Henri Mondor and Institut Pasteur in France.